Intec Pharma Ltd. (NASDAQ:NTEC) – Analysts at Oppenheimer issued their Q1 2018 earnings per share estimates for Intec Pharma in a report issued on Monday, March 12th, according to Zacks Investment Research. Oppenheimer analyst J. Olson forecasts that the biotechnology company will post earnings of ($0.27) per share for the quarter. Oppenheimer has a “Buy” rating on the stock. Oppenheimer also issued estimates for Intec Pharma’s Q2 2018 earnings at ($0.30) EPS, Q3 2018 earnings at ($0.31) EPS, Q4 2018 earnings at ($0.34) EPS, FY2018 earnings at ($1.22) EPS, FY2019 earnings at ($1.25) EPS, FY2020 earnings at ($1.24) EPS and FY2021 earnings at ($1.43) EPS.
Intec Pharma (NASDAQ:NTEC) last released its earnings results on Friday, March 9th. The biotechnology company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19).
A number of other equities research analysts also recently commented on NTEC. Zacks Investment Research downgraded Intec Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, December 19th. HC Wainwright initiated coverage on Intec Pharma in a research report on Monday, February 26th. They set a “buy” rating for the company. Finally, Ladenburg Thalmann Financial Services initiated coverage on Intec Pharma in a research report on Wednesday, February 28th. They set a “buy” rating for the company. Two analysts have rated the stock with a sell rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $12.67.
Shares of NASDAQ:NTEC traded down $0.20 on Thursday, reaching $6.30. 48,289 shares of the company traded hands, compared to its average volume of 58,068. Intec Pharma has a fifty-two week low of $4.80 and a fifty-two week high of $9.80. The company has a market capitalization of $169.49, a PE ratio of -3.82 and a beta of 1.26.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sectoral Asset Management Inc purchased a new stake in shares of Intec Pharma in the third quarter valued at $3,177,000. Caxton Corp purchased a new stake in shares of Intec Pharma in the third quarter valued at $681,000. Pura Vida Investments LLC purchased a new stake in shares of Intec Pharma in the third quarter valued at $895,000. Meitav Dash Investments Ltd. purchased a new stake in shares of Intec Pharma in the fourth quarter valued at $8,607,000. Finally, Deutsche Bank AG lifted its holdings in shares of Intec Pharma by 59.2% in the fourth quarter. Deutsche Bank AG now owns 115,217 shares of the biotechnology company’s stock valued at $593,000 after purchasing an additional 42,867 shares in the last quarter. Institutional investors own 41.39% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Q1 2018 Earnings Estimate for Intec Pharma Ltd. (NASDAQ:NTEC) Issued By Oppenheimer” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/07/intec-pharma-ltd-forecasted-to-post-q1-2018-earnings-of-0-27-per-share-ntec.html.
About Intec Pharma
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Get a free copy of the Zacks research report on Intec Pharma (NTEC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.